Simona Ivančan

Dr. Simona Ivančan


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Emerging Infectious Diseases
Verified
Journal Article
Open access
SISimona Ivančan
Simona Ivančan
MPMarko Pokorn
Marko Pokorn
LKLidija Kitanovski
Lidija Kitanovski
MPManica Mueller Premru
Manica Mueller Premru
JJJanez Jazbec
Janez Jazbec

28 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SISimona Ivančan
Simona Ivančan
KČKlementina Črepinšek
Klementina Črepinšek
BBBarbara Jenko Bizjan
Barbara Jenko Bizjan
RŠRobert Šket
Robert Šket
JKJernej Kovač
Jernej Kovač
TTTine Tesovnik
Tine Tesovnik
Our study aimed to identify relevant transcriptomic biomarkers for the Wilms tumor, the most common pediatric kidney cancer, independent of the histological type and stage. Using next-generation sequencing, we analyzed the miRNA profiles of 74 kidney samples, which were divided into two independent groups: fresh frozen tissue and formalin-fixed paraffin-embedded tissue samples. Subsequent mRNA expression profiling and pathway analysis were performed to establish the interplay and potential involvement of miRNAs and mRNA in the Wilms tumor. Comparative analysis, irrespective of post-dissection tissue processing, revealed 41 differentially expressed miRNAs, with 27 miRNAs having decreased expression and 14 miRNAs having increased expression in the Wilms tumor tissue compared to healthy kidney tissue. Among global mRNA transcriptomic profile differences, cross-sectional analysis suggested a limited list of genes potentially regulated by differentially expressed miRNAs in the Wilms tumor. This study identified the comprehensive miRNA and mRNA profile of the Wilms tumor using next-generation sequencing and bioinformatics approach, providing better insights into the pathogenesis of the Wilms tumor. The identified Wilms tumor miRNAs have potential as biomarkers for the diagnosis and treatment of the Wilms tumor, regardless of histological subtype and disease stage.